Wim Dokter

Company: Byondis

Job title: Chief Scientific Officer

Seminars:

Profile of BYON4228, a Selective Pan-Allelic SIRPα Blocking Antibody Designed to Improve Efficacy of Therapeutic Anti-Tumor Antibodies 12:00 pm

• BYON4228 potentiates both macrophage- and neutrophil-mediated elimination of hematologic and solid cancer cells in vitro in the presence of several different tumor-targeting antibodies. • BYON4228 does not recognize the closely related T-cell expressed SIRPα. • BYON4228 is well tolerated by cynomolgus monkeys. Clinical studies are planned to start in 2022Read more

day: Day Two Track A AM